[go: up one dir, main page]

EA200800336A1 - Лечение состояний, связанных с присутствием макромолекулярных агрегатов, в частности глазных расстройств - Google Patents

Лечение состояний, связанных с присутствием макромолекулярных агрегатов, в частности глазных расстройств

Info

Publication number
EA200800336A1
EA200800336A1 EA200800336A EA200800336A EA200800336A1 EA 200800336 A1 EA200800336 A1 EA 200800336A1 EA 200800336 A EA200800336 A EA 200800336A EA 200800336 A EA200800336 A EA 200800336A EA 200800336 A1 EA200800336 A1 EA 200800336A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
eye disorders
states related
molecular units
chelating
Prior art date
Application number
EA200800336A
Other languages
English (en)
Other versions
EA013931B1 (ru
Inventor
Раджив Бхушан
Джерри Б. Джин
Original Assignee
Чакшу Рисерч Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Чакшу Рисерч Инк. filed Critical Чакшу Рисерч Инк.
Publication of EA200800336A1 publication Critical patent/EA200800336A1/ru
Publication of EA013931B1 publication Critical patent/EA013931B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Предоставляются способ и композиция для лечения медицинских состояний, связанных с образованием и/или отложением макромолекулярных агрегатов, в частности тех, которые связаны с неблагоприятными глазными состояниями. Композиция содержит не цитотоксичный хелатообразующий агент, содержащий по меньшей мере 3 отрицательно заряженных хелатообразующих атома, и маскирующий заряд агент, содержащий по меньшей мере одну полярную группу, и имеющий молекулярную массу менее чем примерно 250, где молярное отношение маскирующего заряд агента к хелатообразующему агенту достаточно для обеспечения того, чтобы, по существу, все отрицательно заряженные хелатообразующие атомы были ассоциированы с полярной группой на маскирующем заряд агенте.
EA200800336A 2005-07-15 2006-07-14 Способ лечения глазных расстройств EA013931B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/182,999 US20060166879A1 (en) 2002-12-20 2005-07-15 Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders
PCT/US2006/027686 WO2007011875A2 (en) 2005-07-15 2006-07-14 Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders

Publications (2)

Publication Number Publication Date
EA200800336A1 true EA200800336A1 (ru) 2008-08-29
EA013931B1 EA013931B1 (ru) 2010-08-30

Family

ID=37441844

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200800336A EA013931B1 (ru) 2005-07-15 2006-07-14 Способ лечения глазных расстройств

Country Status (9)

Country Link
US (1) US20060166879A1 (ru)
EP (1) EP1906918A2 (ru)
JP (1) JP2009501727A (ru)
CN (1) CN101304727A (ru)
AU (1) AU2006270036A1 (ru)
CA (1) CA2615370A1 (ru)
EA (1) EA013931B1 (ru)
IL (1) IL188788A0 (ru)
WO (1) WO2007011875A2 (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006270094A1 (en) * 2005-07-15 2007-01-25 Chakshu Research Inc. Prevention and treatment of ophthalmic complications of diabetes
EP2044951A1 (en) 2007-10-02 2009-04-08 Merz Pharma GmbH & Co. KGaA The use of substances for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases
US9616127B2 (en) * 2008-03-11 2017-04-11 Livionex Inc. Method and topical formulation for treating localized edema
WO2010135731A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
US9622911B2 (en) 2010-09-30 2017-04-18 Cxl Ophthalmics, Llc Ophthalmic treatment device, system, and method of use
EP2830637B1 (en) 2012-03-29 2024-08-21 Epion Therapeutics, Inc. Compositions and methods for treating or preventing diseases associated with oxidative stress
EP2830627B1 (en) 2012-03-29 2024-05-01 Epion Therapeutics, Inc. Ocular treatment solutions, delivery devices and delivery augmentation methods
WO2013148895A1 (en) 2012-03-29 2013-10-03 Cxl Ophthalmics, Llc Ocular cross-linking system and method for sealing corneal wounds
US9526760B2 (en) * 2012-05-21 2016-12-27 The Regents Of The University Of Colorado, A Body Corporate LEDGF peptides and formulations thereof for treatment of degenerative disorders
US10507245B2 (en) 2012-07-19 2019-12-17 Luis Felipe Vejarano Restrepo Ophthalmic formulation and method for ameliorating presbyopia
RU2694758C2 (ru) 2012-12-20 2019-07-16 Раджив Бхушан Антимикробные композиции
RU2683651C2 (ru) * 2013-06-18 2019-04-01 Иван Дмитриевич Захаров Лекарственное средство для лечения кератоконуса и других дегенеративных заболеваний роговицы и фармацевтические препараты на его основе
US20160279055A1 (en) 2013-07-22 2016-09-29 Imprimis Pharmaceuticals, Inc. Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof
US20150164882A1 (en) 2013-07-22 2015-06-18 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
RU2635185C2 (ru) * 2013-12-17 2017-11-09 Иван Дмитриевич Захаров Фармацевтический препарат для профилактики и лечения прогрессирующей близорукости
US10512402B2 (en) 2015-04-22 2019-12-24 Board Of Trustees Of Northern Illinois University Non-invasive occular biomarkers for early diagnosis of diseases
US20210085696A1 (en) * 2018-02-05 2021-03-25 LIVIONEX, Inc. Formulations comprising chelators, permeation enhancers and hydroxyethyl cellulose for treating ophthalmic disorders
KR20220034199A (ko) 2019-09-18 2022-03-17 알콘 인코포레이티드 습식-패킹 소프트 하이드로겔 안구 삽입물
KR20230015955A (ko) * 2020-05-26 2023-01-31 산텐 세이야꾸 가부시키가이샤 노시의 치료 또는 예방에 유용한 황 함유 화합물
WO2023069037A1 (en) * 2021-10-19 2023-04-27 Vsy Biyoteknoloji Ve Ilac Sanayi Anonim Sirketi Ophthalmic formulations for treatment of presbyopia, dry eye disease and computer vision syndrome
WO2024180472A1 (en) 2023-02-28 2024-09-06 Alcon Inc. Ocular inserts

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342784A (en) * 1964-10-06 1982-08-03 E. R. Squibb & Sons, Inc. Chemical compositions and method of utilization
US4450150A (en) * 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US4087538A (en) * 1976-09-09 1978-05-02 Merck & Co., Inc. Ophthalmic suspensions
US4294853A (en) * 1979-06-13 1981-10-13 Abbott Laboratories Biocidal additive for cutting fluids
US4863748A (en) * 1979-08-30 1989-09-05 Herschler R J Dietary products and uses comprising methylsulfonylmethane
US4296130A (en) * 1979-08-30 1981-10-20 Herschler R J Methylsulfonylmethane and methods of use
US4390542A (en) * 1980-12-02 1983-06-28 Schachar Ronald A Method for inhibiting contraction of opthalmic wounds or incisions
US4510145A (en) * 1980-12-02 1985-04-09 Schachar Ronald A Method for inhibiting contraction of ophthalmic wounds or incisions
FR2588189B1 (fr) * 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
US5032392A (en) * 1986-09-04 1991-07-16 Vision Pharmaceuticals Aqueous ophthalmic solutions for the treatment of dryness and/or irritation of human or animal eyes
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US4923693A (en) * 1988-01-21 1990-05-08 Sundrops Enterprises, Inc. Ultraviolet radiation screening method for eyes
US5360611A (en) * 1988-10-03 1994-11-01 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment of the cornea following ultraviolet laser irradiation
US5278142A (en) * 1989-03-20 1994-01-11 Orbon Corporation Systemic delivery of polypeptides through the eye
US5182258A (en) * 1989-03-20 1993-01-26 Orbon Corporation Systemic delivery of polypeptides through the eye
US5221696A (en) * 1989-03-29 1993-06-22 Alcon Laboratories, Inc. Use of monoacyl phosphoglycerides to enhance the corneal penetration of ophthalmic drugs
US5660851A (en) * 1989-12-26 1997-08-26 Yissum Research Development Company Of The Hebrew Univ. Of Jerusalem Ocular inserts
US5300295A (en) * 1990-05-01 1994-04-05 Mediventures, Inc. Ophthalmic drug delivery with thermoreversible polyoxyalkylene gels adjustable for pH
US5525601A (en) * 1990-09-07 1996-06-11 Universidad De Alicante Composition for treating ocular pain
EP0666753B9 (en) * 1991-09-09 2002-06-12 Peptech Limited Use of peptides FOR THE TREATMENT OF THE COMPLICATIONS AND PATHOLOGY OF DIABETES
ZA927277B (en) * 1991-10-02 1993-05-19 Boston Ocular Res Dry eye treatment process and solution.
US5270051A (en) * 1991-10-15 1993-12-14 Harris Donald H Enzyme-orthokeratology
US5318780A (en) * 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
US6015834A (en) * 1992-10-20 2000-01-18 Toronto Neuroprotection Group In vivo treatment of mammalian cells with a cell membrane permeant calcium buffer
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
WO1995013827A1 (en) * 1993-11-19 1995-05-26 The University Of Sydney A method for preventing or controlling cataract
US5443824A (en) * 1994-03-14 1995-08-22 Piacquadio; Daniel J. Topical thalidomide compositions for surface or mucosal wounds, ulcerations, and lesions
WO1995034302A2 (en) * 1994-06-16 1995-12-21 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of calcium chelators
JPH08175984A (ja) * 1994-12-21 1996-07-09 Shionogi & Co Ltd 後発白内障予防剤
CA2210684C (en) * 1995-01-18 2008-01-15 Alteon Inc. Use of thiazolium compounds for preventing and reversing the formation of advanced glycosylation endproducts
FI119756B (fi) * 1995-01-18 2009-03-13 Alteon Inc Tiatsoliumyhdisteiden käyttö pitkälle edenneen glykosylaation lopputuotteiden muodostumisen estossa ja suunnan muutoksessa
US5824685A (en) * 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
US6492420B2 (en) * 1995-03-10 2002-12-10 Photocure As Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
JP4167728B2 (ja) * 1996-02-07 2008-10-22 ロート製薬株式会社 粘度を調節した眼科用組成物
AU745028B2 (en) * 1996-10-14 2002-03-07 Kissei Pharmaceutical Co. Ltd. Secondary cataract inhibitor
US6410046B1 (en) * 1996-11-19 2002-06-25 Intrabrain International Nv Administering pharmaceuticals to the mammalian central nervous system
MX9701946A (es) * 1997-03-14 1998-04-30 Arturo Jimenez Bayardo Solucion oftalmica transportadora.
US5817630A (en) * 1997-03-18 1998-10-06 Austin Nutriceutical Corporation Glutathione antioxidant eye drops
ES2205462T3 (es) * 1997-03-31 2004-05-01 Alza Corporation Sistema de suministro por dufusion, implantable.
US5811446A (en) * 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
US6265444B1 (en) * 1997-05-23 2001-07-24 Insite Vision Incorporated Ophthalmic composition
US6159458A (en) * 1997-11-04 2000-12-12 Insite Vision Sustained release ophthalmic compositions containing water soluble medicaments
US6555522B1 (en) * 1998-02-05 2003-04-29 Mount Sinai School Of Medicine Of The City Of New York Peptides and other small molecules derived from regions of interacting proteins and uses thereof
US6197934B1 (en) * 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
EP1124582B1 (en) * 1998-10-27 2003-12-10 Alcon Laboratories, Inc. Preservative system for topically administrable pharmaceutical compositions
US6171337B1 (en) * 1999-03-31 2001-01-09 Miles A. Galin Positive power anterior chamber ocular implant
ATE260099T1 (de) * 1999-04-05 2004-03-15 Hope City Neue hemmern von fortgeschrittenen glykosilierung-endprodukten
US6399093B1 (en) * 1999-05-19 2002-06-04 Advanced Medical Instruments Method and composition to treat musculoskeletal disorders
US6548059B1 (en) * 1999-07-22 2003-04-15 The Schepens Eye Research Institute, Inc. Promotion of proliferation of adult corneal endothelial cells
ATE270558T1 (de) * 1999-08-26 2004-07-15 Ganeden Biotech Inc Verwendung von emu-öl als träger für fungizide, antibakterielle und antivirale arzneien
US6573299B1 (en) * 1999-09-20 2003-06-03 Advanced Medical Instruments Method and compositions for treatment of the aging eye
US6653352B2 (en) * 1999-09-29 2003-11-25 Medical Merchandising, Inc. Pain reliever and method of use
CA2385703A1 (en) * 1999-10-07 2001-04-12 Human Genome Sciences, Inc. Plasminogen-like polynucleotides, polypeptides, and antibodies
US6331313B1 (en) * 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US6489335B2 (en) * 2000-02-18 2002-12-03 Gholam A. Peyman Treatment of ocular disease
US6348508B1 (en) * 2000-04-04 2002-02-19 Bausch & Lomb Incorporated Method for treating dry eye
RU2165749C1 (ru) * 2000-07-06 2001-04-27 Общество с ограниченной ответственностью "Научно-экспериментальное производство Микрохирургия глаза" Способ восстановления эндотелия роговицы
US6579519B2 (en) * 2000-09-18 2003-06-17 Registrar, University Of Delhi Sustained release and long residing ophthalmic formulation and the process of preparing the same
AU2001291159A1 (en) * 2000-09-20 2002-04-02 Shahinian Jr., Lee Self-preserved nasal, inhalable, and topical ophthalmic preparations and medications
US6328987B1 (en) * 2000-11-03 2001-12-11 Jan Marini Skin Research, Inc. Cosmetic skin care compositions containing alpha interferon
US7084130B2 (en) * 2001-12-11 2006-08-01 Alcon, Inc. Intraocular irrigating solution having improved flow characteristics
US6713081B2 (en) * 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
US6533769B2 (en) * 2001-05-03 2003-03-18 Holmen Joergen Method for use in cataract surgery
US20030065292A1 (en) * 2001-06-08 2003-04-03 Darouiche Rabih O. Ozonated medical devices and methods of using ozone to prevent complications from indwelling medical devices
US20030083286A1 (en) * 2001-08-22 2003-05-01 Ching-Leou Teng Bioadhesive compositions and methods for enhanced intestinal drug absorption
KR20040058100A (ko) * 2001-11-14 2004-07-03 알자 코포레이션 주입가능한 데포 조성물 및 그의 용도
US20030114460A1 (en) * 2001-12-14 2003-06-19 Allergan Sales, Inc. Pharmaceutical conjugates with enhanced pharmacokinetic characteristics
CN1741811A (zh) * 2002-03-29 2006-03-01 马克西姆医药公司 Rom产生与释放抑制剂治疗和预防眼内损伤的用途
US20040038864A1 (en) * 2002-06-27 2004-02-26 Per Balschmidt Use of dimethyl sulfone as isotonicity agent
NZ540885A (en) * 2002-12-20 2009-02-28 Chakshu Res Inc Ophthalmic formulation for the prevention and treatment of ocular conditions
ITMI20030195A1 (it) * 2003-02-06 2004-08-07 Bsd Bioscience Dev Snc Di O Mini C E Zucc Formulazioni topiche contenenti principi attivi naturali adatte alla prevenzione e cura dei processi infiammatori delle mucose
AU2006270094A1 (en) * 2005-07-15 2007-01-25 Chakshu Research Inc. Prevention and treatment of ophthalmic complications of diabetes

Also Published As

Publication number Publication date
WO2007011875A2 (en) 2007-01-25
JP2009501727A (ja) 2009-01-22
CA2615370A1 (en) 2007-01-25
IL188788A0 (en) 2008-08-07
EP1906918A2 (en) 2008-04-09
WO2007011875A3 (en) 2007-08-23
US20060166879A1 (en) 2006-07-27
EA013931B1 (ru) 2010-08-30
CN101304727A (zh) 2008-11-12
AU2006270036A1 (en) 2007-01-25

Similar Documents

Publication Publication Date Title
EA200800336A1 (ru) Лечение состояний, связанных с присутствием макромолекулярных агрегатов, в частности глазных расстройств
MX2021009667A (es) Compuestos de tioeno[3,2-b] piridin-7-amina para tratar la disautonomía familiar.
WO2019195761A3 (en) Pharmacological agents for treating ocular diseases
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
EA201190303A1 (ru) ПРОИЗВОДНЫЕ 1,2,4-ТРИАЗОЛО[4,3-а]ПИРИДИНА И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДУПРЕЖДЕНИЯ НЕВРОЛОГИЧЕСКИХ И ПСИХИАТРИЧЕСКИХ РАССТРОЙСТВ
EA200900663A1 (ru) Лечение синдрома "сухого глаза"
BG105880A (en) Compounds useful as anti-inflammatory agents
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
EA201190301A1 (ru) ПРОИЗВОДНЫЕ 1,2,4-ТРИАЗОЛО[4,3-а]ПИРИДИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2
BRPI0412893A (pt) composto, composição farmacêutica, uso de um composto, e, métodos de prevenção, tratamento ou melhora de doenças ou condições inflamatórias, ou doenças ou condições oftálmicas, de tratamento ou melhora de cáncer e para a produção de um composto
EA200700617A1 (ru) Новые пиридиновые производные и их применение в качестве позитивных аллостерических модуляторов mglur2-рецепторов
BRPI0512220A (pt) método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
CY1107467T1 (el) Χρηση οξεογονων υδρογονοτροφων στελεχων για την προληψη ή την αγωγη πεπτικων διαταραχων
TW200633709A (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions
EA200100623A1 (ru) Кетолидные антибиотики
ATE191143T1 (de) Verwendung von nichtsteroidalen cyclooxygenasehemmern zur herstellung eines medikaments zur behandlung vom erhoehten augeninnendruck
DE69928567D1 (de) Biodegradierbare polyphosphoester-zusammensetzungen zur behandlung von ovarialkrebs
BR0015416A (pt) Composições contendo derivados do ácido hidroxieicosa tetraenóico e métodos de uso no tratamento de distúrbios de olhos secos
DE602006019948D1 (de) Koppelten rezeptors zur behandlung von makuladegeneration
BR9914128A (pt) Composições antibióticas para tratamento do olho, ouvido e nariz
BRPI0506970A (pt) derivados de alfa-aminoamida úteis no tratamento de distúrbios do trato urinário inferior
MXPA05008561A (es) Uso de esteroides para tratar personas que sufren de trastornos oculares.
DE60016181D1 (de) C-16 ungesätigte fp-selektive prostaglandin analoge
MX2022007094A (es) Compuestos para tratar la disautonomía familiar.
WO2005115432A3 (en) Treatment of ocular diseases and disorders using lantibiotic compositions

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU